Compounded semaglutide and compounded tirzepatide are still legally available and in stock as fall 2026 arrives. Both drugs came off the FDA drug shortage list in 2024–2025, compounding pharmacies adjusted their supply chains, and patients are filling prescriptions without widespread disruption. But a long-anticipated FDA rulemaking decision is expected before December 31 — and it will determine what compounded semaglutide looks like for years to come.
By Alexandru Vieru | Independently researched | Last updated: September 2026. Regulatory data reflects FDA public records and analysis through August 2026.
Bottom line for fall 2026: Compounded semaglutide prepared by a 503A-licensed pharmacy for an individual prescription remains legal in all 50 states. Clinics in our ranking are fulfilling orders normally. The FDA 503B rulemaking — which governs large-scale compounding operations, not your individual prescription — is expected to reach a final decision in Q4 2026. Even if the rule finalizes, most telehealth GLP-1 programs would continue operating under 503A rules.
What Is Compounded Semaglutide — and Why Does It Come in Two Legal Flavors?
When a telehealth clinic ships you semaglutide or tirzepatide, the medication is compounded — prepared by a licensed pharmacy using pharmaceutical-grade bulk ingredients, formulated to your specific prescription. Compounded semaglutide is not a generic version of Wegovy; it's a custom preparation made legal by one of two federal frameworks.
| Framework | Who it covers | Who makes it | Fall 2026 status |
|---|---|---|---|
| 503A pharmacy | Patient-specific prescriptions (the telehealth model) | State-licensed pharmacies compounding per individual Rx | ✅ Operating normally |
| 503B outsourcing facility | Batch production without patient-specific Rx | FDA-registered facilities at scale | ⚠️ Under active rulemaking — final decision expected Q4 2026 |
Most telehealth GLP-1 programs — including every clinic in our ranking — are built around the 503A model. A licensed prescriber reviews your intake, writes a prescription for you specifically, and a 503A-registered pharmacy compounds and ships it.
The pending rulemaking news that generates anxiety is aimed at 503B facilities, not 503A pharmacies. If you're on a telehealth program today, your supply is 503A.
Why the Shortage Ending Matters for Compounded Semaglutide Supply
The events that created the compounded GLP-1 market:
While a drug is on the FDA's drug shortage database, a specific legal exemption allows 503A and 503B compounders to produce compounded versions at broader scale, even using the same active pharmaceutical ingredient (API) as the brand-name drug. That exemption drove the expansion of compounded semaglutide and tirzepatide starting in 2022.
The shortage designations have since been removed:
- Tirzepatide (Mounjaro/Zepbound) was removed from the FDA shortage list in October 2024.
- Semaglutide (Wegovy/Ozempic) was removed in February 2025.
Once a drug leaves the shortage list, the broad shortage exemption closes. Compounders had to shift from shortage-authorized production to the baseline 503A/503B framework — which has stricter requirements and, for 503B specifically, is now under active rulemaking review.
What this meant in practice: Clinics relying on the shortage exemption had to adapt their supply chains by spring 2025. Programs that survived that transition — including those in our ranking — are now operating under durable 503A authority. The shortage ending didn't kill compounded semaglutide; it matured the supply chain in ways that benefited well-run programs over pop-up dispensaries.
For the historical context, see Semaglutide Shortage 2026: What Changed and Is Compounded Semaglutide Still Legal in 2026?.
The FDA 503B Rulemaking: Timeline and What Falls 2026 Buyers Should Know
April 2026: FDA published a proposed rule to remove semaglutide and tirzepatide from the list of bulk drug substances that 503B outsourcing facilities may use to produce compounded medications. The proposal would end large-scale batch compounding by 503B facilities.
June 30, 2026: The public comment period closed. FDA received comments from patients, pharmacy boards, telehealth companies, compounding pharmacies, and manufacturers.
Q3–Q4 2026 (now): FDA is reviewing those comments and drafting a final rule. A Q4 2026 decision is widely anticipated. The FDA's compounding resource page tracks all active guidance as it publishes.
The two likely scenarios:
| Scenario | What changes for 503B | What stays the same for 503A patients |
|---|---|---|
| FDA finalizes the exclusion | 503B facilities can no longer bulk-produce compounded semaglutide or tirzepatide | 503A telehealth programs continue; your individual prescription is unaffected |
| FDA delays or modifies the rule | Status quo continues; 503B facilities keep operating | 503A programs unaffected either way |
What a 503B restriction could affect: Batch production at 503B scale drives down unit costs. If 503B supply exits the market, 503A-compounded semaglutide may cost modestly more per dose — though by how much depends on how supply chains reorganize. We'll update pricing in our cheapest compounded semaglutide guide as Q4 unfolds.
For the full regulatory status, see Compounded Semaglutide FDA Update: Q3 2026.
Is Compounded Semaglutide Still Safe to Use in Fall 2026?
Legality and safety are related but distinct questions. The active pharmaceutical ingredient in compounded semaglutide is the same API used in Wegovy — the molecule is well-characterized. What FDA doesn't individually review is the compounding process at each specific pharmacy.
That's why compounded semaglutide verification markers matter:
For the pharmacy your clinic uses:
- LegitScript certification — independently verifiable at legitscript.com; confirms national dispensing standards
- USP-797 compliance — the sterile compounding standard required for injectable medications
- US-licensed pharmacists and state pharmacy board registration in good standing
- Cold-chain shipping — semaglutide and tirzepatide require temperature-controlled delivery; plain-box shipping is a red flag
For your prescriber:
- A licensed US physician or nurse practitioner reviewing your full intake before any prescription
- A titration protocol matching established clinical practice (starting low, escalating gradually)
- Monitoring and follow-up built into the program, not just an initial consult
Every clinic in our ranking meets these baseline criteria as a condition of inclusion. See the GLP-1 Buyer Safety Hub for the complete 6-signal vetting checklist.
What Fall 2026 Buyers Should Actually Do About Compounded Semaglutide
If you're already on a compounded semaglutide or tirzepatide program:
-
Don't stockpile unnecessarily. Current supply from licensed 503A pharmacies is stable. Any regulatory change that finalizes in Q4 would include an implementation window — it wouldn't cut off supply overnight. Stock one refill ahead if your clinic allows it.
-
Ask your clinic about their supply chain. Direct question: "Is my compounded semaglutide from a 503A-registered pharmacy?" A legitimate program answers immediately. Vague answers warrant follow-up.
-
Check whether your program has a brand-name fallback. Some programs — like Wellorithm, which offers both compounded and brand-name Wegovy/Zepbound — can route you to brand-name GLP-1 if compounded supply tightens. That optionality is worth a modest premium if supply resilience matters to you.
-
Watch FDA's announcement timeline. When the final rule publishes, read the implementation schedule before reacting. A rule with a 90-day implementation window gives your clinic time to adjust before it touches your prescription.
If you're considering starting compounded semaglutide this fall:
Starting now carries no higher regulatory risk than starting earlier this year. 503A pharmacies are operating normally; your individual prescription is not what the 503B rulemaking targets.
Practical checklist for choosing a program:
- Compare all-in monthly cost, not just the starting dose — maintenance doses are almost always higher
- Verify LegitScript status independently, not from the clinic's own page
- Confirm US board-certified prescribers are reviewing your intake
- Ask for the titration schedule in writing before you pay
- Understand the refill policy and what happens if you need to pause
See our semaglutide eligibility and intake guide for 2026 for who qualifies and how the intake process works.
Our Top Picks for Compounded Semaglutide in Fall 2026
These programs use 503A-licensed, LegitScript-certified pharmacies. All are currently fulfilling prescriptions normally.
1. Wellorithm — Best Overall + Brand-Name Fallback
Wellorithm scores at the top of our independent ranking for clinical quality. It offers compounded semaglutide and tirzepatide under 503A, plus access to brand-name Wegovy and Zepbound — the most supply-resilient program in our ranking if 503B rules tighten. Board-certified physicians review all prescriptions.
2. HealthRX — Best Starting Price for Compounded Semaglutide
HealthRX offers the lowest verified starting price for compounded semaglutide in our ranking, on a 12-month commitment plan. LegitScript certified, 503A USP-797 compliant, with US board-certified physicians responding in under 24 hours.
3. Gala Health — Best for GLP-1 + Hormonal Health
Gala Health combines compounded semaglutide programs with hormone therapy under one telehealth intake — the only program in our ranking with that integrated offering. Strong transparency score.
⚠️ Medical disclaimer: Compounded semaglutide and tirzepatide are not FDA-approved for any indication. FDA approves drug manufacturers, not individual compounding pharmacies. This article provides legal and supply context only — it is not medical advice. Consult a licensed clinician before starting or changing any GLP-1 program.
Affiliate disclosure: We earn a commission if you click through and purchase from a clinic in our ranking. This does not affect our editorial scoring or the order of our public ranking. Full affiliate disclosure → | Editorial policy →
FAQs: Compounded Semaglutide Fall 2026
Is compounded semaglutide still legal in fall 2026? Yes. Compounded semaglutide prepared for individual patient prescriptions by 503A-licensed pharmacies remains legal in all 50 states. The pending FDA 503B rulemaking targets large-scale outsourcing facilities, not the individual-prescription 503A model used by telehealth clinics.
Will the FDA ban compounded semaglutide in Q4 2026? No ban on 503A-compounded semaglutide is expected. If the FDA finalizes the 503B exclusion, large-scale outsourcing facilities face restrictions — but the telehealth model (503A, individual prescriptions) continues under existing law. No complete ban is expected under any scenario currently on the table.
Has the semaglutide shortage ended? Yes. Semaglutide was removed from the FDA drug shortage list in February 2025. Tirzepatide was removed in October 2024. Compounded supply under 503A authority continues legally and is currently stable going into fall 2026.
What is the difference between 503A and 503B compounding for patients? 503A pharmacies compound semaglutide for your specific prescription — your prescriber writes an Rx for you, and the pharmacy makes it for you. 503B outsourcing facilities produce compounded medication in larger batches without requiring patient-specific prescriptions. The FDA's proposed rule specifically targets 503B. If you're using a telehealth program, you're on 503A.
Should I stock up on compounded semaglutide before the FDA ruling? No. Current supply is stable, and any regulatory change finalizing in Q4 2026 would include an implementation window — it wouldn't cut off supply overnight. Stocking more than one refill ahead creates unnecessary financial strain without meaningfully protecting you.
How do I verify my clinic uses a legitimate compounding pharmacy for semaglutide? Look up the pharmacy name directly on LegitScript.com — don't rely on the clinic's claim. The pharmacy should also disclose its state registration and USP-797 sterile compounding compliance. See the GLP-1 Buyer Safety Hub for the complete 6-signal checklist.
Related Reading
- Compounded Semaglutide FDA Update: Q3 2026 Status — What FDA did after the comment period closed
- Is Compounded Semaglutide Still Legal in 2026? — Full 503A/503B legal framework
- Semaglutide Shortage 2026: What Changed — How the shortage ending reshaped the market
- Cheapest Compounded Semaglutide Online 2026 (Verified) — Current all-in pricing across reviewed clinics
- GLP-1 Weight Loss Cost Guide 2026 — Cost landscape for compounded and brand-name
- GLP-1 Buyer Safety Hub — How to vet any online GLP-1 clinic before you enroll
